Results 161 to 170 of about 126,669 (262)

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19. [PDF]

Obesity (Silver Spring), 2021
de Ligt M, Hesselink MKC, Jorgensen J, Jocken JWE, Blaak EE, Goossens GH.   +5 more
europepmc   +1 more source

POLIMORFISME GEN ANGIOTENSIN II TYPE 1 RECEPTOR (A1166C) SEBAGAI FAKTOR RISIKO PADA PASIEN DENGAN HIPERTENSI ESENSIAL DI KABUPATEN CIREBON

Tiar Masykuroh Pratamawati, Ikrama Akbarahma, Ahmad Fariz Malvi Zamzam Zein, Catur Setiya Sulistiyana, Eni Suhaeni, Donny Nauphar   +5 more
openalex   +2 more sources

Erratum: Corrigendum: Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states [PDF]

, 2007
Ronald D. Cohn, Christel van Erp, Jennifer Habashi, Arshia Soleimani, Erin C. Klein, Matthew T Lisi, Matthew Gamradt, Colette M ap Rhys, Tammy M. Holm, Bart Loeys, Francesco Ramirez, Daniel P. Judge, Christopher W. Ward, Harry C. Dietz   +13 more
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Angiotensin II type-1 receptor autoantibodies and effects in neonates of women with preeclampsia. [PDF]

BMC Pregnancy Childbirth
Ponthier L, El Hamel C, Coste Mazeau P, Martinez S, Wehbe S, Froget R, Yardin C, Guigonis V.   +7 more
europepmc   +1 more source

Arginine-Vasopressin Neurons in the Rat Hypothalamus Produce Neurokinin B and Co-express the Tachykinin NK-3 Receptor and Angiotensin II Type 1 Receptor.

, 2001
Takashi Hatae, Hitoshi Kawano, Vladimir Karpitskiy, James E. Krause, Sadahiko Masuko   +4 more
openalex   +2 more sources

A state of reversible compensated ventricular dysfunction precedes pathological remodelling in response to cardiomyocyte specific Angiotensin II type-1 receptor activity [PDF]

, 2015
G. Alkistis Frentzou, Mark J. Drinkhill, Neil A. Turner, Stephen G. Ball, Justin Ainscough   +4 more
openalex   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Angiotensin II Type-1 Receptor Antibody in Solid Organ Transplantation - Is It Time to Test? [PDF]

Transpl Int
Martin PJP, Willicombe M, Roufosse C.
europepmc   +1 more source